Financial Disclosure Applies To Firms Providing Drugs For Public Studies
This article was originally published in The Tan Sheet
Executive Summary
Pharmaceutical companies that contribute drugs to publicly funded studies used to support marketing applications will be responsible for collecting investigator financial interest information, an updated financial disclosure guidance notes.
You may also be interested in...
Investigator Financial Disclosure Revised Rule Limits Retrospective Reports
Retrospective collection of financial information about clinical investigators' equity interests in publicly traded companies has been eliminated from FDA's final rule on Financial Disclosure by Clinical Investigators.
Supplement GMP Warning Letters Make Modest Debut In 2010
Finalization of a settlement between the Federal Trade Commission and Rexall Sundown regarding unsupported cellulite treatment claims for the firm's Cellasene dietary supplement hinges upon approval of two related class action settlements pending in California and Florida, according to FTC
In Brief
Combe sells most of its OTC brands